Article Text

other Versions

PDF
MBDA: what is it good for?
  1. Yusuf Yazici1,
  2. Christopher J Swearingen2
  1. 1New York University School of Medicine, Seligman Center for Advanced Therapeutics, NYU Hospital for Joint Diseases, New York, New York, USA
  2. 2Department of Pediatrics, Genetics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
  1. Correspondence to Dr Yusuf Yazici, New York University School of Medicine, Seligman Center for Advanced Therapeutics, NYU Hospital for Joint Diseases, New York, NY 10016, USA; yusuf.yazici{at}nyumc.org

Statistics from Altmetric.com

We read with interest the paper by Hambardzumyan et al1 studying the predictive value of multibiomarker disease activity (MBDA) score in rheumatoid arthritis (RA) for radiographic progression (RP) using the SWEFOT study data. In review, the SWEFOT trial enrolled individuals who had active RA with average DAS28 scores of above 52; 235 subjects in the SWEFOT trial were included in the current analysis. The authors state that when MBDA score at baseline was low (n=5) or moderate (n=29), only one patient had RP, defined as an increase by more than 5 points in the Van der Heijde-modified Sharp score (SHS) over 1 year. When baseline MBDA score was high, 42 out of 201 patients (21%) had a 5-points worsening of SHS at 1 year. While the specificity and positive predictive value of MBDA to predict RP were …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles